DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claims 1, 2 and 4-9 are pending in the application.
This office action is in response to the amendment filed on 8/11/2026.
All previous rejection not reiterated in this office action are withdrawn.
Specification
The amendment filed 8/11/2026 is objected to under 35 U.S.C. 132(a) because it introduces new matter into the disclosure. 35 U.S.C. 132(a) states that no amendment shall introduce new matter into the disclosure of the invention. The added material which is not supported by the original disclosure is as follows: Example 7 paragraph [0198]-[0202].
Applicant is required to cancel the new matter in the reply to this Office Action.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 1, 2, 4-9 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Regarding claim 1, the amended claim recites “and the nucleotide sequence has a homology >= 90% SEQ ID NO: 1…SEQ ID NO: 2 and SEQ ID NO: 3” renders the claim indefinite because it is unclear whether the nucleotide sequence is referring to nucleotide sequence A, B and C, or including variants of said A, B and C.
Dependent claims 2, 4-9 are rejected for same reason because they depend on claim 1 but does not remedy the indefiniteness.
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 1, 2, 4-6 and 8-9 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This rejection is rewritten to address the amendment.
The written description requirement is set forth by 35 U.S.C. 112, first paragraph which states that the: “specification shall contain a written description of the invention. . .[emphasis added].” The written description requirement has been well established and characterized in the case law. A specification must convey to one of skill in the art that “as of the filing date sought, [the inventor] was in possession of the invention.” See Vas Cath v. Mahurkar 935 F.2d 1555, 1560 19 USPQ2d 1111, 1117 (Fed. Cir. 1991). Applicant may show that he is in “possession” of the invention claimed by describing the invention with all of its claimed limitations “by such descriptive means as words, structures, figures, diagrams, formulas, etc., that fully set forth the claimed invention.” See Lockwood v. American Airlines Inc. 107 F.3d 1565, 1572, 41 USPQ2d 1961, 1966 (Fed. Cir. 1997).
In analyzing whether the written description requirement is met, it is first determined whether a representative number of species have been described by their complete structure. Next, it is determined whether a representative number of species have been sufficiently described by other relevant identifying characteristics.
Amended claim 1 recites A) African swine fever virus derived p72 variants formed by substitution, deletion or addition of one or more amino acid residues in the amino acid sequence of the capsid protein p72 and have the function of the capsid protein p72; B) African swine fever virus derived B602L variants formed by substitution, deletion or addition of one or more amino acid residues in the amino acid sequence of the accessory protein B602L and have the function of prompting the accurate expression and folding of the capsid protein p72 or variants thereof; and C) African swine fever derived CD2V variants formed by substitution, deletion or addition of one or more amino acid residues in the amino acid sequence of the exterior envelope protein CD2V and have the function of the exterior envelope protein CD2V, and the nucleotide sequences having >=90% identity with SEQ ID NO: 1, 2 and 3. As discussed in the above 112b rejection, it is unclear whether this newly added sequence information is directed to nucleotide sequence A, B and C only, or encompasses the variants. Claim 6 recites an African swine fever derived p49 variants formed by substitution, deletion or addition of one or more amino acid residues in the amino acid sequence of the capsid protein p49 and have the function of the capsid protein p49. The claimed p72, B602L, CD2V and p49 encompasses a large genus of polypeptides that comprises a large amount of mutations or combination of mutations thereof, including not only substitution, but also addition and deletion in or more amino acid residues encoding said protein, which result in polypeptide of varying lengths and structure. The specification teaches codon optimized p72, B602L and CD2V isolated from Georgia 2007/1 strain African swine fever virus encoded by SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 were expressed by a recombinant pseudorabies virus and administered to Balb/c mice. The specification teaches the serum of mice produces antibodies that can bind to p72 and CD2V. However, the specification does not teach any “variants” of said p72, p49, B602L and CD2V with substitution, addition and/or deletion of one or more amino acids that retains the function of the wild type p72, p49, B602L and CD2V as claimed. The specification does not teach any sequence with 90% homology with SEQ ID NO: 1, 2 and 3 that has the same function.
The knowledge in prior art does not make up such deficiency. In a review article, Chen et al (Viruses 2024, Vol. 16, no. 913, pages 1-18) teach ASFV is a complex double stranded DNA virus with genome sizes varying from 170 to 195 kilobase pairs, and comprises three distinct regions. Chen et al. teach the left and right variable region (LVR and RVR) contribute to genetic diversity with B646L (encodes p72) and EP402R (encodes CD2v) being used to make classification (page 2nd paragraph, and Figure 1 and legend). Chen et al. teach the changes in viral genome caused by insertions and deletions may severely affect the protein’s function, leading to loss of the entire functional protein, with major implications for viral adaptation and evolution (page 3, 4-6). Based on such teaching, whether “variants” formed by substitution, insertion and/or deletion of one or more amino acid residue within the amino acid sequence encoding p72, p49, B602L and CD2V may still retain the function of wild type amino acid sequence would be unpredictable.
In view of the large genus of “variant” claimed in claim 1, claim 6 and dependent claims thereof (2-7, and 8-9), the specification does not describe a representative number of species by their complete structure, nor other identifying characteristics for the claimed function. A skilled in the art thus cannot immediately envision the structure of the variants based on the function of said proteins. Therefore, the specification fails to describe the claimed genus of variants sufficiently to reasonably convey a skilled in the art that the inventor had possession of the invention at the time the application was filed.
Claim 9 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.
There are many factors to be considered when determining whether there is sufficient evidence to support a determination that a disclosure does not satisfy the enablement requirement and whether any necessary experimentation is "undue." These factors include, but are not limited to: (a) the nature of the invention; (b) the breadth of the claims; (c) the state of the prior art; (d) the amount of direction provided by the inventor; (e) the existence of working examples; (f) the relative skill of those in the art; (g) whether the quantity of experimentation needed to make or use the invention based on the content of the disclosure is "undue"; and (h) the level of predictability in the art (MPEP 2164.01 (a)).
Nature of the invention
Claims 9 is drawn to an African swine fever vaccine comprises the recombinant PRV that comprises nucleotide A, B and C, which encodes p72, B602L, and CD2V, and variants thereof.
The teaching from the specification and the presence of working examples
The specification teaches the recombinant PRV vaccine is used for treating and preventing ASF (paragraph 0071]). The specification teaches treating or preventing involves the administration of animals in need with effective dosage to treat animals already infected with AFSV and show clinical syndromes caused by ASFV, or before infection by ASFV to decrease the severe degree of clinic syndrome or morbidity of ASFV (paragraph [0072]-[0073]). The specification teach codon optimized p72, B602L and CD2V isolated from Georgia 2007/1 strain African swine fever virus encoded by SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 were expressed by a recombinant pseudorabies virus, wherein the genes encoding p72, B602L and CD2V are inserted into non-essential replication region of PRV TK coding region and gG coding region. The specification teaches the recombinant PRV were administered into Balbc mice, and the serum of mice produces antibodies that can bind to p72 and CD2V. However, the specification does not teach whether administering the recombinant PRV encoding p72, B602L and CD2V can protect an animal such as a pig from infection from ASFV and develop African swine fever or whether it can ameliorate symptoms of ASF in an animal already infected. As such, whether the claimed recombinant PRV can be a ASF vaccine is unpredictable based on the teaching from the specification.
The teaching from prior art and the level of unpredictability in the art
In a review article, Chen et al (Viruses 2024, Vol. 16, no. 913, pages 1-18) teach ASFV is a complex double stranded DNA virus with genome sizes varying from 170 to 195 kilobase pairs, and comprises three distinct regions. Chen et al. teach the left and right variable region (LVR and RVR) contribute to genetic diversity with B646L (encodes p72) and EP402R (encodes CD2v) being used to make classification (page 2nd paragraph, and Figure 1 and legend). Chen et al. teach the strain specificity of the virulence-associated genes in ASFV, resulting from its complex genomic structure, is a major impediment to vaccine research and development and a formidable obstacle to effective ASF control (page 2, 2nd paragraph, bottom lines). Chen et al. teach low fidelity DNA repair pathway and the frequency of viral recombination enhances virus’ genetic diversity and its ability to resist host immune responses and therapeutic interventions (page 3, 1st and 2nd paragraph). Based on such teaching, whether a recombinant PRV encoding p72, B602L and CD2V may be used as a vaccine for treating and/or preventing ASF is unpredictable.
The amount of experimentation required
Due to lack of teaching from instant specification, and the complexity of ASFV genome that contributes to significant obstacle for develop an effective vaccine as discussed in the current state of art, a skilled artisan would need to engage in undue experimentation to use the claimed recombinant PRV as vaccine for protecting and/or treating ASF in an animal. Therefore, the claimed invention of claims 9 and 10 is not enabled by the instant specification.
Response to Arguments
In response to the above rejection, Applicant argues that 1) the mere data that administration of rPRV in Balbc mouse to produce an antibody of binding p72 and CD2v does not mean that effect of rPRV as a vaccine is not predictable. Applicant states that it is well known PRV belongs to Herpes virus subfamily of Herpetoviridae and it has a wide host range including the livestock such as pigs, dogs, cows, goats and wild animals and contains non-essential genes for virus replication, has a large volume of exogenous genes, presents a stable recombinant PRV genetic characters and its exogenous genes cannot be easily lost. Applicant states that this means that the applicant only has to provide one of the applicable animals such as a mouse to verify its immunogenic effect and its capability of vaccine is instead predictable.
The arguments set forth above is under the title claim rejection -35 USC 112. However, there are two separate 112 rejections in the previous office action as reproduced above (written description for claims 1, 2, 4-6 and 8-9, and enablement for claim 9). It is unclear which rejection this argument is directed to. The written description is directed to variants of p72, B602L, and CD2V, which encompasses deletion, insertion and substitution that are not described in the specification, as well as sequences SEQ ID NO: 1, 2 and 3 that has variation up to 10%. As discussed in the above 112b rejection, the claims are ambiguous and not clearly set forth that variants are limited to 90% and above sequence identity. Even it does, the specification does not describe any of such variants that can have the same function as proteins that encoded by wild type SEQ ID NO: 1, 2, and 3. Since the claim does not set forth what function the claim is limited to, the argument that mouse model is sufficient is irrelevant in the present case.
Applicant argues 2) Chen et al’s enlightenment for predictability where the rPRV expressing p72, B602L and CD2V is used as the vaccine of treatment and/or prevention of ASF. Applicant states that P72 derived from ASF virus is the main protein that constitutes the capsid of the ASFV particle, accounting for one third of the total protein content of the virus, and it is a key target for triggering an immune response, together with partner protein B602L, CD2V, are ideal target for protective antigens. Applicant asserts that p72, B602L and CD2v form a good combination to jointly trigger effective immune protection. Applicant argues that p72 derived from ASFV and CD2v from ASFV do not relate to the fidelity of DNA and they are not in the recombinant area, which means they do not relate to the ability of resisting host immune response and therapeutic intervention. Applicant asserts that it can be known that antigenic protein p72, B602L and CD2v are actually designed based on ASFV and rPV containing sequences expressing p72, B602L and CD2v is bound to be capable of treating and/or preventing ASF. Applicant argues that when the sequence similarity of two genes reaches 90%, it indicates they have almost identical three-dimensional structure and function.
Again, since it is unclear which rejection this argument is directed to, Applicant is referring to the same response as given above in the answer to the first argument. However, the examiner does not agree the notion that any nucleic acid sequence similarity reaches 90% would have identical three dimensional structure and function because sequence similarity alone cannot predict function.
Applicant argues 3) changes to the variant of SEQ ID NO: 1, 2, and 3 do not relate to point mutations at the active center nor domain recombination so that variants over 90% homology with SEQ ID NO: 1, 2, and 3 do not fail in the exception of huge impact.
This argument is not persuasive because there is no limitation in the rejected claims where insertion, deletion and/or substitution occurs.
Applicant added experimental data for the ASF virus vaccine to support ASFV in claim 9.
As indicated in the objection to the specification section, no new data may be introduced after the filing date of the specification because they are considered new matter. The examiner also wish to clarify that the previous office action did not recommend introducing new experimental data to the specification. Applicant is reminded that specification must be enabling as of the filing date (MPEP 2164.05 (a)). If Applicant wishes to introducing evidence that the claimed invention works, Applicant may file declaration to introduce such evidence.
Conclusion
THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to CELINE X QIAN whose telephone number is (571)272-0777. The examiner can normally be reached M-F (8-4:00).
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jennifer Dunston can be reached at 571-272-2916. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/CELINE X QIAN/ Primary Examiner, Art Unit 1637